SEC Form 4 · accession 0001325812-17-000038
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laurie Keating
Officer — SVP, GC & Secretary
Period of report
Dec 20, 2017
Accepted (ET)
Dec 21, 2017 · 5:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 20, 2017 | M | 6,249 | $42.22 | A | 17,749 | D | |
| Common StockF2 | Dec 20, 2017 | S | 4,049 | $120.8833 | D | 13,700 | D | |
| Common StockF3 | Dec 20, 2017 | S | 1,900 | $121.6747 | D | 11,800 | D | |
| Common StockF4 | Dec 20, 2017 | S | 300 | $122.5333 | D | 11,500 | D | |
| Common StockF5 | holding | — | — | — | 257 | I | by Managed Account |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance Based Stock Option 2016 (right to buy) | $42.22 | Dec 20, 2017 | A | 6,250 | A | Dec 20, 2017 | Dec 20, 2026 | Common Stock | 6,250 | 6,250 | D |
| Stock Option (right to buy)F7 | $42.22 | Dec 20, 2017 | M | 6,249 | D | — | Dec 20, 2026 | Common Stock | 6,249 | 18,751 | D |
Explanation of responses
- F1All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017.
- F2Sale prices ranged from $120.45 to $121.40.
- F3Sale prices ranged from $121.49 to $122.39.
- F4Sale prices ranged from $122.51 to $122.58.
- F5The reporting person owns 257 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
- F6On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective December 20, 2017, the compensation committee of the Company determined the first performance criterion had been met and the option vested as to one-quarter of the shares.
- F7The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.